{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:18:22Z","timestamp":1792761502725,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008069","name":"University of California, San Francisco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.euf.2025.04.027","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T15:41:31Z","timestamp":1747237291000},"page":"61-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Gleason Grade Group 3 Represents a Spectrum of Disease: Results from a Large Institutional Cohort"],"prefix":"10.1016","volume":"12","author":[{"given":"Kevin","family":"Shee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Kuang Cornelia","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lufan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Greenland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffry P.","family":"Simko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"3rd","given":"Samuel L.","family":"Washington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuto","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao G.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Cooperberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.04.027_b0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.04.027_b0010","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): prostate cancer version 4.2022. Plymouth Meeting, PA: NCCN; 2022."},{"key":"10.1016\/j.euf.2025.04.027_b0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41391-023-00766-z","article-title":"Genomic classifiers and prognosis of localized prostate cancer: a systematic review","volume":"28","author":"Boyer","year":"2025","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euf.2025.04.027_b0020","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eururo.2019.06.023","article-title":"Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: a Cochrane systematic review and meta-analysis","volume":"77","author":"Drost","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.04.027_b0025","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2019.07.051","article-title":"Improved prostate cancer biopsy grading by incorporation of invasive cribriform and intraductal carcinoma in the 2014 grade groups","volume":"77","author":"van Leenders","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.04.027_b0030","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/his.15231","article-title":"Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage","volume":"85","author":"Nguyen","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.euf.2025.04.027_b0035","doi-asserted-by":"crossref","first-page":"310.e7","DOI":"10.1016\/j.urolonc.2018.03.011","article-title":"Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance","volume":"36","author":"Lin","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.04.027_b0040","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1002\/cncr.26169","article-title":"The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy","volume":"117","author":"Cooperberg","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2025.04.027_b0045","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/01.ju.0000158155.33890.e7","article-title":"The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy","volume":"173","author":"Cooperberg","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.04.027_b0050","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.euf.2025.04.027_b0055","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A contemporary prostate cancer grading system: a validated alternative to the Gleason score","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.04.027_b0060","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.eururo.2016.11.031","article-title":"Validation of a contemporary five-tiered Gleason grade grouping using population-based data","volume":"71","author":"He","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.04.027_b0065","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.eururo.2016.11.032","article-title":"Application of a prognostic Gleason grade grouping system to assess distant prostate cancer outcomes","volume":"71","author":"Leapman","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.04.027_b0070","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.eururo.2015.11.036","article-title":"Evaluation of the 2015 Gleason grade groups in a nationwide population-based cohort","volume":"69","author":"Loeb","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.04.027_b0075","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1200\/JCO.2008.20.4669","article-title":"Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?","volume":"27","author":"Stark","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.04.027_b0080","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0090-4295(00)00753-6","article-title":"Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy","volume":"56","author":"Chan","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.euf.2025.04.027_b0085","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3389\/fonc.2019.00646","article-title":"Nomograms predict survival advantages of Gleason score 3+4 over 4+3 for prostate cancer: a SEER-based study","volume":"9","author":"Zhu","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.euf.2025.04.027_b0090","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy","volume":"64","author":"Zumsteg","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.04.027_b0095","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2004.01.164","article-title":"Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease","volume":"22","author":"D\u2019Amico","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.04.027_b0100","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1001\/jamaoncol.2020.4922","article-title":"Development and validation of a clinical prognostic stage group system for nonmetastatic prostate cancer using disease-specific mortality results from the International Staging Collaboration for Cancer of the Prostate","volume":"6","author":"Dess","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2025.04.027_b0105","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/pros.23977","article-title":"Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4","volume":"80","author":"Greenland","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.euf.2025.04.027_b0110","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/JU.0000000000001290","article-title":"The prognostic impact of intraductal carcinoma of the prostate: a systematic review and meta-analysis","volume":"204","author":"Miura","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.04.027_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2020.12.004","article-title":"Stage and grade migration in prostate cancer treated with radical prostatectomy in a large German multicenter cohort","volume":"19","author":"Boehm","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euf.2025.04.027_b0120","doi-asserted-by":"crossref","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","article-title":"U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement","volume":"157","author":"Moyer","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euf.2025.04.027_b0125","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/cncr.31337","article-title":"PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening","volume":"124","author":"Kearns","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2025.04.027_b0130","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/pcan.2016.30","article-title":"Increasing incidence of metastatic prostate cancer in the United States (2004\u20132013)","volume":"19","author":"Weiner","year":"2016","journal-title":"Prostate Cancer Prostat Dis"},{"issue":"5","key":"10.1016\/j.euf.2025.04.027_b9000","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.11869","article-title":"Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality","volume":"5","author":"Burgess","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925001063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925001063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:57:42Z","timestamp":1770145062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925001063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2405456925001063"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.04.027","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gleason Grade Group 3 Represents a Spectrum of Disease: Results from a Large Institutional Cohort","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}